Abstract
Immunotherapy-induced hepatitis is a well-known and relatively common side effect of immune checkpoint inhibitors. It is usually mild to moderate and responds well to corticosteroids with a full recovery. However, in rare cases, severe liver injury may develop, leading to fulminant liver failure. In this case report, we present a case of acute fulminant liver failure with a fatal outcome despite adequate treatment in a 67-year-old male following a combination therapy of carboplatin, pemetrexed, and pembrolizumab for metastatic lung cancer.
Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Aged
-
Antibodies, Monoclonal, Humanized* / administration & dosage
-
Antibodies, Monoclonal, Humanized* / adverse effects
-
Antineoplastic Agents, Immunological / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols* / adverse effects
-
Carboplatin* / administration & dosage
-
Carboplatin* / adverse effects
-
Chemical and Drug Induced Liver Injury / etiology
-
Fatal Outcome
-
Humans
-
Liver Failure, Acute / chemically induced
-
Lung Neoplasms* / drug therapy
-
Male
-
Pemetrexed* / administration & dosage
-
Pemetrexed* / adverse effects
Substances
-
pembrolizumab
-
Pemetrexed
-
Antibodies, Monoclonal, Humanized
-
Carboplatin
-
Antineoplastic Agents, Immunological